Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2007, vol. 16, nr 2, March-April, p. 317–322

Publication type: review article

Language: English

The Roles of Inflammatory Markers, Hemostasis Factors, and Oxidative Stress in the Pathogenesis of Polycystic Ovary Syndrome

Rola czynników stanu zapalnego, czynników hemostazy i stresu oksydacyjnego w patogenezie zespołu wielotorbielowatych jajników

Agnieszka Lenarcik1,, Bożena Bidzińska−Speichert1,

1 Chair and Department of Endocrinology and Diabetology, Silesian Piasts University of Medicine in Wrocław, Poland

Abstract

Polycystic ovary syndrome (PCOS) affects 5 to 10% of women in reproductive age. In the pathogenesis of PCOS, hormonal disorders (ovarian and pituitary), insulin resistance and, recently, chronic inflammation are taken into account. The markers of low−grade chronic inflammation which are considered with regard to the inflammatory theory of PCOS are C−reactive protein, interleukin−6, tumor necrosis factor−α, fibrinogen, tissue plasminogen activator, plasminogen activator inhibitor−1, and as well as homocysteine, paraoxonase 1, interleukin−18, procalcitonin, and white blood cell count. Results of the latest studies concerning serum inflammatory markers and their relationships in women with PCOS are presented here.

Streszczenie

Zespół wielotorbielowatych jajników (PCOS – polycystic ovary syndrome) dotyczy 5–10% kobiet w wieku rozrodczym. W patogenezie tego zespołu są brane pod uwagę zaburzenia hormonalne (jajnikowe i przysadkowe), insulinooporność, a ostatnio również przewlekły proces zapalny. Do wykładników stanu zapalnego, rozpatrywanych w kontekście teorii zapalnej PCOS, należą: białko C−reaktywne, interleukina−6, czynnik martwicy nowotworu−α, fibrynogen, tkankowy aktywator plazminogenu, inhibitor pierwszy tkankowego aktywatora plazminogenu, a także homocysteina, paraoksonaza 1, interleukina−18, prokalcytonina i liczba leukocytów we krwi. W pracy przedstawiono najnowsze badania kliniczne, w których oceniano stężenia we krwi oraz wzajemne korelacje markerów stanu zapalnego u kobiet z PCOS.

Key words

PCOS, inflammation, C−reactive protein, interleukin−6, tumor necrosis factor−α

Słowa kluczowe

PCOS, zapalenie, białko C−reaktywne, interleukina−6, czynnik martwicy nowotworu−α

References (39)

  1. Stein IF, Leventhal ML: Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935, 29, 181–191.
  2. Kahn CR, Goldstein BJ: Molecular defects in insulin action. Science 1989, 245, 13–16.
  3. Burghen GA, Givens JR, Kitabchi AE: Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980, 50, 113–116.
  4. Rotterdam ESHRE/ASRM−Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long−term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81, 1, 19–25.
  5. Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B: Central fat excess in polycystic ovary syndrome: relation to low−grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005, 90, 11, 6014–6021.
  6. Orio F Jr, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanova L, Nardo LG, Labella D, Savastano S, Russo T, Zullo F, Colao A, Lombardi G: The increase of leukocytes as a new putative marker of low−grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90, 1, 2–5.
  7. Escobar−Morreale HF, Botella−Carretero JI, Villuendas G, Sancho J, San Milan JL: Serum interleukin−18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab 2004, 89, 2, 806–811.
  8. Pepys MB: C−reactive protein. Fifty years on. Lancet 1981, 1, 653–657.
  9. Kelly CCJ, Lyall H, Petrie JR, Gould GW, Connell JMC, Sattar N: Low Grade Chronic Inflammation in Women with Polycystic Ovarian Syndrome. J Clin Endocrinol Metab 2001, 86, 6, 2453–2455.
  10. Talbott EO, Zborowski JV, Boudreaux MY, McHugh−Pemu KP, Sutton−Tyrrell K, Guzick DS: The Relationship between C−Reactive Protein and Carotid Intima−Media Wall Thickness in Middle−Aged Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2004, 89, 12, 6061–6067.
  11. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z: Increased C−Reactive Protein Levels in the Polycystic Ovary Syndrome: A Marker of Cardiovascular Disease. J Clin Endocrinol Metab 2004, 89, 5, 2160–2165.
  12. Fenkci V, Fenkci S, Yilmazer M, Serteser M: Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003, 80, 123–127.
  13. Trujillo ME, Sullivan S, Harten I, Schneider SH, Greenberg AS, Fried SK: Interleukin−6 regulates human adipose tissue lipid metabolism and leptin production in vitro. J Clin Endocrinol Metab 2004, 89, 5577–5582.
  14. Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J: Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003, 52, 942–947.
  15. Festa A, D’Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102, 42–47.
  16. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B: Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000, 85, 9, 3338–3342.
  17. Yudkin JS, Kumari M, Humphries SE, Mohamed−Ali V: Inflammation, obesity, stress and coronary heart disease: is interleukin−6 the link? Atherosclerosis 2000, 148, 209–214.
  18. Villuendas G, San Millan JL, Sancho J, Escobar−Morreale HF: The 597 G−A and 174 G−C polymorphisms in the promoter of the IL−6 gene are associated with hyperandrogenism. J Clin Endocrinol Metab 2002, 87, 1134–1141.
  19. Escobar−Morreale HF, Calvo RM, Villuendas G, Sancho J, San Millan JL: Association of polymorphisms in the interleukin 6 receptor complex with obesity and hyperandrogenism. Obes Res 2003, 11, 987–996.
  20. Möhlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AFH, Schill T, SchlösserHW, Brabant G, Schöfl C: The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004, 150, 525–532. Inflammatory Theory of PCOS 321 sue of obese people [15, 20], directly inducing insulin resistance by influencing the pathway of changes released by insulin binding with its receptor. On the other hand, inflammatory factors activating the hypothalamo−pituitary−adrenal axis favor central obesity and secondary insulin resistance [17, 34]. In recent reports, authors have revealed elevated levels of low−grade chronic inflammatory factors and substances related to hemo
  21. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS−1−mediated inhibition of insulin receptor tyrosine kinase activity in TNFα and obesity−induced insulin resistance. Science 1996, 271, 665–668.
  22. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor−α in human obesity and insulin resistance. J Clin Invest 1995, 95, 2409–2415.
  23. Gonzalez F, Thusu K, Abdel−Rahman E, Prabhala A, Tomani M, Dandona P: Elevated serum levels of tumor necrosis factor−α in normal−weight women with polycystic ovary syndrome. Metabolism 1999, 48, 4, 437–441.
  24. Sayin NC, Gucer F, Balkanli−Kaplan P, Yuce MA, Ciftci S, Kucuk M, Yardim T: Elevated serum TNF−alpha in normal−weight women with polycystic ovaries or the polycystic ovary syndrome. J Reprod Med 2003, 48, 3, 165–170.
  25. Spaczynski RZ, Arici A, Duleba AJ: Tumor necrosis factor−α stimulates proliferation of rat ovarian theca−interstitial cells. Biol Reprod 1999, 61, 993–998.
  26. Escobar−Morreale HF, Calvo RM, Sancho J, San Millan JL: TNF−α and Hyperandrogenism: A Clinical, Biochemical and Molecular Genetic Study. J Clin Endocrinol Metabol 2001, 86, 8, 3761–3767.
  27. Kelly CJG, Lyall H, Petrie JR, Gould GW, Connell JMC, Rumley A, Lowe GDO, Sattar N: A Specific Elevation in Tissue Plasminogen Activator Antigen in Women with Polycystic Ovarian Syndrome. J Clin Endocrinol Metab 2002, 87, 7, 3287–3290.
  28. Atiomo WU, Bates SA, Condon JE, Shaw S, West JH, Prentice AG: The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 1998, 69, 2, 236–241.
  29. Atiomo WU, Fox R, Condon JE, Shaw S, Friend J, Prentice AG, Wilkin TJ: Raised plasminogen activator inhibitor−1 (PAI−1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2000, 52, 4, 487–492.
  30. Glueck CJ, Wang P, Fontaine RN, Sieve−Smith L, Tracy T, Moore SK: Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999, 48, 1589–1595.
  31. Gonzalez F, Rote NS, Minium J, Kirwan JP: Reactive oxygen species−induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 10, 1210, 2005, 1696.
  32. Barnes PJ, Karin M: Nuclear factor−κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997, 336, 1066–1071.
  33. Evans JL, Maddux BA, Goldfine ID: The molecular basis for oxidative stress−induced insulin resistances. Antioxid Redox Signal 2005, 7, 7–8, 1040–1052.
  34. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS−1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF−α and obesity−induced insulin resistance. Science 1996, 271, 665–668.
  35. Yarali H, Yildirir A, Aybar F, Kabakci G, Bukulmez O, Akgul E, Oto A: Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril 2001, 76, 511–516.
  36. Vrbikova J, Bicikova M, Tallova J, Hill M, Starka L: Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2002, 110, 74–76.
  37. Loverro G, Lorusso F, Mei L, Depalo R, Cormio G, Selvaggi L: The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest 2002, 53, 157–162.
  38. Bayraktar F, Dereli D, Ozgen AG, Yilmaz C: Plasma homocysteine levels in polycystic ovary syndrome and congenital adrenal hyperplasia. Endocr J 2004, 51, 6, 601–608.
  39. San Millán JL, Cortón M, Villuendas G, Sancho J, Peral B, Escobar−Morreale HF: Association of the Polycystic Ovary Syndrome with Genomic Variants Related to Insulin Resistance, Type 2 Diabetes Mellitus, and Obesity. J Clin Endocrinol Metabol 2004, 89, 6, 2640–2646.
© Wroclaw Medical University